Blaine Varner
Medical · Sumter, SCNPI 1629257142
Payments from drug & device makers
Across 152 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$629
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$478
- AbbVie$341
- Otsuka America Pharmaceutical, Inc.$297
- Sunovion Pharmaceuticals Inc.$252
- Johnson & Johnson$190
- plus $682 from 7 others
What the payments were for
- Food & beverage$2,70894%
- Education$1606%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 39 | $629 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $478 |
| AbbVie | 21 | $341 |
| Otsuka America Pharmaceutical, Inc. | 14 | $297 |
| Sunovion Pharmaceuticals Inc. | 17 | $252 |
| Johnson & Johnson | 7 | $190 |
| Alkermes, Inc. | 9 | $176 |
| Vanda Pharmaceuticals Inc. | 7 | $146 |
| Teva Pharmaceuticals USA, Inc. | 8 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $106 |
| Axsome Therapeutics, Inc. | 3 | $93 |
| Eisai Inc. | 1 | $15 |
| Indivior Inc. | 1 | $15 |
How this compares
$2,868 in reported general payments places this provider in the 75th percentile of 384 medical providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 15 | $42,139 |
| Aripiprazole | 74 | $6,689 |
| Lurasidone Hcl | 26 | $6,640 |
| Bupropion XlBupropion Hcl | 13 | $2,429 |
| Ramelteon | 15 | $2,272 |
| Oxcarbazepine | 23 | $1,920 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 17 | $1,631 |
| Duloxetine Hcl | 62 | $1,408 |
| Olanzapine | 36 | $1,211 |
| Quetiapine Fumarate | 37 | $1,010 |
| Gabapentin | 49 | $873 |
| Hydroxyzine Hcl | 28 | $599 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $573 |
| Buspirone Hcl | 57 | $569 |
| Clonazepam | 47 | $552 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $297 | $42,13915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 384 medical providers in South Carolina.
Other medical in Sumter
- Christopher ThompsonSpartanburg$78K
- Laura BuchGreenville$73K
- Suzanne SmithWest Columbia$39K
- Stavros ChrysostomidesColumbia$39K
- Ethan CaseySpartanburg$24K
- Jessica HallColumbia$22K
- Mary MacdonaldCharleston$20K
- Cameron PappasGreenville$18K
- Leslie RumbautGrenville$18K
- Claire DukeGreenville$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.